Cell-Free DNA Analysis in Maternal Plasma in Cases of Fetal Abnormalities Detected on Ultrasound Examination
Authors:
- Alexandra BenachiABAlexandra Benachi
- Alexandra LetourneauALAlexandra Letourneau
- Pascale KleinfingerPKPascale Kleinfinger
- Marie-Victoire SenatMSMarie-Victoire Senat
- Evelyne GautierEGEvelyne Gautier
- Romain FavreRFRomain Favre
- Laurent BidatLBLaurent Bidat
- Véronique Houfflin-DebargeVHVéronique Houfflin-Debarge
- Jean BouyerJBJean Bouyer
- Jean-Marc CostaJCJean-Marc Costa
- 1 June 2015
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 125 (6) , 1330-1337
Abstract
To evaluate the utility of noninvasive prenatal testing using cell-free circulating fetal DNA for detection of the three main autosomal fetal trisomies in the setting of ultrasonographically identified fetal anomalies. Nine hundred patients at risk for fetal aneuploidy with or without ultrasonography anomalies and who underwent invasive procedures were included in the study. Cell-free DNA analysis was performed by massive parallel sequencing during a multicenter, noninterventional, prospective study and the results were compared with a fetal karyotype. Among all 900 pregnancies, cell-free DNA identified 76 of 76 (100%) fetal Down syndrome, 22 of 25 (88%) trisomy 18, and 12 of 12 (100%) trisomy 13. In those with a normal ultrasonogram and normal cell-free DNA analysis, karyotype identified 2 of 483 (0.4%) additional aneuploidies other than trisomies 13, 18, and 21. In those with an abnormal ultrasonogram and a normal cell-free DNA analysis, there were 23 of 290 (7.9%) additional pathogenic karyotypes. These additional aneuploidies included sex chromosome abnormalities and triploidy. The rates of additional aneuploidies not identifiable by standard cell-free DNA screening in the two groups is significantly different at P<.01. In women with fetal abnormalities by ultrasonography, the rate of pathogenic chromosome abnormalities missed by cell-free DNA was 8%. Noninvasive prenatal testing should not be offered to women with fetal abnormalities because a negative result is falsely reassuring. IIIKeywords
This publication has 18 references indexed in Scilit:
- Maternal Plasma Fetal DNA Fractions in Pregnancies with Low and High Risks for Fetal Chromosomal AneuploidiesPLOS ONE, 2014
- Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal DiagnosisPrenatal Diagnosis, 2013
- High-Throughput Massively Parallel Sequencing for Fetal Aneuploidy Detection from Maternal PlasmaPLOS ONE, 2013
- Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic CounselorsJournal of Genetic Counseling, 2013
- Committee Opinion No. 545Obstetrics & Gynecology, 2012
- Clinical application of massively parallel sequencing‐based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factorsPrenatal Diagnosis, 2012
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation studyGenetics in Medicine, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011